Nuvalent, INC. (NUVL) — 10-Q Filings

10-Q Filings (6)

• Nuvalent's Q3 Net Loss Widens 45% Amid Soaring R&D Costs — Oct 30, 2025 Risk: high
  Nuvalent, Inc. (NUVL) reported a significant increase in net loss for the three months ended September 30, 2025, reaching $122.4 million, up from $84.3 million
• Nuvalent's Q2 Loss Widens to $75.2M Amid R&D Surge — Aug 7, 2025 Risk: high
  Nuvalent, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company's net loss for the t
• Nuvalent Files Q1 2025 10-Q, Details Drug Pipeline — May 8, 2025 Risk: medium
  Nuvalent, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business operations, including details on
• Nuvalent Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Nuvalent, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position and operations, including details on comm
• Nuvalent Files 10-Q: Financials and Equity Details — Aug 8, 2024 Risk: medium
  Nuvalent, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details the company's financial position, including common stock and retained earn
• Nuvalent, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  Nuvalent, Inc. (NUVL) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Nuvalent, Inc. filed a 10-Q report for the period ending March 31, 2024. The

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX